Injectable compositions

Details Injectable compositions Injectable compositions

1998-12-31

2001-04-10

Page, Thurman K. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C424S424000, C424S426000

Reexamination Certificate

active

06214367

ABSTRACT:

TECHNICAL FIELD OF THE INVENTION
This invention relates to novel compositions of macrolide avermectin and milbemycin endecticides with an immunising agent and in particular it relates to a stable injectable composition for use with warm-blooded animals, in particular ruminants.
The use of a combination of an parasitic agent and immunising agent as a single injectable formulation offers advantages both in time and cost saving to the farmer.
BACKGROUND
New Zealand Patent Nos. 191413 and 193807 of ICI Tasman Limited disclose water based formulations of D, L-tetramisole and clostridial vaccine in the treatment of helminthiasis and clostridial diseases in warm-blooded animals. Both D, L-tetramisole and the clostridial vaccine are water soluble hence a combination of the two is straight forward. What was surprising was that the clostridial vaccine remained effective at a pH lower than 6.0 and that the combination improved the immune response in ruminants, though not in other animals.
These aqueous formulations commonly used an adjuvant such as alum or alum hydroxide to enhance the effect of the antigen. Such adjuvants are usually included in the formulation as an aqueous suspensions. The vaccines can then be readily mixed with water based anthelmintic formulations.
Since the use of D, L-tetramisole and more particularly the L-isomer levamisole, there have been a number of other potent antiparasitic macrocyclic lactone compounds such as the avermectins, ivermectin, doramectin, abamectin, milbemycin, moxidectin used in the treatment of diseases in warm blooded animals. These later parasiticides are insoluble in water which creates difficulties in formulating stable injectable compositions. However, the compounds have the advantage that they are active against internal and external parasites in domestic animals.
Formulations are therefore based on co-solvent systems or aqueous solvent Systems utilising a water-soluble solvent with one or more wetting agents. Water soluble solvents mix readily with traditional aqueous adjuvant systems to form combinations of anthelmintics and vaccines. This is not the case with oil based (non-aqueous) systems.
OBJECT
It is an object of the invention to provide an improved injectable composition combining a parasitic agent and an antigen or at least one that provides the public with a useful choice.
STATEMENT OF INVENTION
It has been surprisingly discovered that non-aqueous anthelmintics can be combined with an antigen using an oil as an adjuvant and carrier to give a stable formulation that can be safely injected into warm blooded animals including cattle and sheep.
In one aspect the invention comprises a stable injectable composition comprising a non-aqueous parasitic agent in a therapeutically effect amount and an antigen in combination with a liquid carrier that also acts as an adjuvant for use with warm blooded animals.
Preferably the non-aqueous parasitic agent is a macrolide compound selected from group comprising avermectin, ivermectin, doramectin, abamectin, milbemycin and moxidectin, present in from 0.05 to 10% w/v.
More preferably the non-aqueous parasitic agent is chosen from the group comprising abamectin, ivermectin, moxidectin and doramectin.
Preferably, the carrier is an oil, either a vegetable oil such as sesame oil, saponine oil, soya bean oil, and corn oil or a mineral adjuvant oil, such as paraffin oil, or purified derivatives of vegetable or mineral oils, such as quiala, which is suitable for injection into animals or a mixture thereof. The oil acts as an adjuvant for the immunising agent and may also act as a solvent for the anthelmintic. The oil also extends the action of the parasitic agent.
Additionally, the composition may further contain an oil soluble solvent. The oil soluble solvent is chosen from the group comprising alcohols having four or more carbon atoms for example benzyl alcohol, ethylbenzyl alcohol, phenethyl alcohol and other aromatic monohydric alcohols.
Preferably the alcohol is present in the range from 10-50 w/v %.
The antigen is incorporated into the composition by emulsifying it in a suitable emulsion agent, for example sorbiten oleate (Span 80™ or Liposorb 80™). Other suitable emulsion agents may also be used. The emulsifier is present in the range of from 5-50 w/v %.
Antigens suitable to be used in the compositions include antigens derived from bacterial and viral pathogens of warm-blooded animals. Preferably the antigen is chosen from the group comprising antigens derived from and toxins of clostridial diseases including
Clostridium septicum, Clostridium tetani, Clostridium chauvoei, Clostridium novyi, Clostridium sordelli
and
Clostridium haemolytica
. Other possible antigens include Pasteurella,
Pasteurella maltocida
and
Corynebacterium pseudotuberculosis
and viral antigens for Infectious Bovine Rhinotracheitis, Bovine Viral Diarrhoea and Parainfluenza.
In another aspect, the invention comprises a method of treating parasitic diseases and preventing viral and bacterial diseases in warm blooded animals by administration to an animal of a composition as described above.
Preferably the composition is administered to the animal by injecting the animal.
Preferably the composition is administered at the rate of 0.5-5 mL/50 kg bodyweight of the animal.


REFERENCES:
patent: 3579633 (1971-05-01), Thomson
patent: 4199569 (1980-04-01), Chabala et al.
patent: 4292307 (1981-09-01), Zemlyakova
patent: 4310519 (1982-01-01), Albers-Schonberg et al.
patent: 4606918 (1986-08-01), Allison et al.
patent: 4781920 (1988-11-01), Quinlan
patent: 5262400 (1993-11-01), Chu et al.
patent: 5550153 (1996-08-01), Kerz
patent: 5639876 (1997-06-01), Tripp et al.
patent: 5733566 (1998-03-01), Lewis
patent: 0 181 525 (1986-05-01), None
patent: 0 215 313 (1987-03-01), None
patent: 0 750 907 (1997-01-01), None
patent: 1171125 (1969-11-01), None
patent: 2 050 830 (1981-01-01), None
patent: 183847 (1977-04-01), None
patent: 186852 (1978-04-01), None
patent: 186851 (1978-04-01), None
patent: 188460 (1978-09-01), None
patent: 188459 (1978-09-01), None
patent: 199817 (1982-02-01), None
patent: WO 94/26113 (1994-11-01), None
P. Lammie et al., “Alterations in Filarial Antigen-Specific Immunologic Reactivity Following Treatment with Ivermectin and Diethylcarbamazine”, Am. J. Trop. Med. Hyg., vol. 46, No. 3, 1992, pp. 292-295.
D. Fink et al., “Pharmacokinetics of Ivermectin in Animals and Humans”, Ivermectin and Abamectin, Chapter 7.
Joseph R. Robinson et al., Controlled Drug Delivery Fundamentals and Applications, Second Edition, pp. 452-457.
H. Stone, “Efficacy of Experimental Animal and Vegetable Oil-Emulsion Vaccines for Newcastle Disease and Avian Influenza”, Avian Diseases, vol. 37, 1993, pp. 399-405.
J. Freund et al., “Antibody Formation and Sensitization with the Aid of Adjuvants”, , Apr. 13, 1948, pp. 383-398.
O. Umehara et al., “Compatability between doramectin and foot-and-mouth disease vaccine administered simultaneously to cattle”, vol. 2, No. 2, 1993.
H. Akuffo et al., “Ivermectin-induced immunopotentation in onchocerciasis: recognition of selected antigens following a single dose of ivermectin”, Clin. Exp. Immunol., vol. 103, 1996, pp. 244-252.
C.L. Schwartzkoff et al., “Australian Veterinary Journal”, Biological Abstracts, vol. 102, Issue 009, Ref. 140304.
R. Bomford, “Adjuvants for Anti-parasite Vaccines”, Parasitology Today, vol. 5, No. 2, 1989, pp. 41-46.
Cyanamid, “Cydectin Eweguard 6 in 1 Vaccine and Wormer For Adult Sheep”, Animal Remedies Board, License No. A 07302.
R. Gupta et al., “Adjuvants—a balance between toxicity and adjuvanticity”, Vaccine, vol. 11, Issue 3, 1993, pp. 293-306.
S. R. Wicks et al., “Effect of formulation on the pharmacokinetics and efficacy of doramectin”, Veterinary Parasitology, vol. 49, 1993 pp. 17-26.
Philip J. Willson et al., “Tissue Reaction and Immunity in Swine Immunized withActinobacillus pleuropneumoniaeVaccines”, Can. J. Vet. Res., vol. 59, 1995, pp. 299-305.

Affiliated with

Also associated with

Rating

Injectable compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Injectable compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Injectable compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2525390